For experts

2026. 04. 08

New C2H Report: Brivaracetam (Briviact)

2025. 12. 10

New C2H Report: Capivasertib (Truqap)

2025. 11. 14

New C2H Report: Elranatamab (Elrexfio)

2019. 03. 06

International symposium - Current status and future role of HTA in Japan and other countries